glp-1 obesity drug news today sep 30 2025 Pill Helped People With Lose Almost Pounds in New Trial Eli Lilly's Obesity Pill Shows

People with Graves disease are at a greater risk of developing a vitamin B12 deficiency

However, 20% of participants discontinued the pemvidutide 2.4 mg due to AE with the most common being nausea and vomiting - the discontinuation rate was 519% with lower doses [74]

Occludin, claudin-5, and claudin-8 were found to be downregulated and redistributed, whereas claudin-2 (pore-forming TJ protein) was strongly upregulated

This article, Weight Loss in Lactation, from the InfantRisk Centre discusses this further

Your provider will Review your BMI symptoms goals history medications to determine whether GLP-1 therapy is clinically appropriate for you. This ensures you get a treatment plan that fits your needs, not a one-size-fits-all approach

In the meantime, there has also been the first attempt to create a gene therapy that could integrate a GLP-1 secreting transgene directly into pancreas beta cells